You are here

  • Home
  • Archive
  • Volume 28, Issue 4
  • Neoadjuvant Bleomycin, Etoposide, and Cisplatin (BEP) Chemotherapy in the Treatment of Extensively Advanced Yolk Sac Tumors: A Single Center Experience

Article info

Article menu
Download PDFPDF
Ovarian Cancer
Neoadjuvant Bleomycin, Etoposide, and Cisplatin (BEP) Chemotherapy in the Treatment of Extensively Advanced Yolk Sac Tumors: A Single Center Experience

Authors

  • Gong-yi Zhang Department of Gynecological Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. PubMed articlesGoogle scholar articles
  • Rong Zhang Department of Gynecological Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. PubMed articlesGoogle scholar articles
  • Ling-ying Wu Department of Gynecological Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. PubMed articlesGoogle scholar articles
  • Bin Li Department of Gynecological Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. PubMed articlesGoogle scholar articles
  • Shu-min Li Department of Gynecological Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. PubMed articlesGoogle scholar articles
  1. Address correspondence and reprint requests to Rong Zhang, MD, Department of Gynecological Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan, Chaoyang District, Beijing 100021, China. E-mail: super0078888{at}sina.com.

Citation

Zhang G, Zhang R, Wu L, et al
Neoadjuvant Bleomycin, Etoposide, and Cisplatin (BEP) Chemotherapy in the Treatment of Extensively Advanced Yolk Sac Tumors: A Single Center Experience
International Journal of Gynecologic Cancer 2018;28:713-720.

Publication history

  • Received June 16, 2017
  • Accepted January 3, 2018
  • First published May 1, 2018.
Online issue publication 
January 27, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2018 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.